Abstract:Abstract The majority of p53 missense mutations identified in cancer patients are in the DNA-binding domain and are characterized as either structural or contact mutations. These missense mutations exhibit inhibitory effects on wild-type p53 activity. More importantly, these mutations also demonstrate gain-of-function (GOF) activities characterized by increased metastasis, poor prognosis, and drug resistance. To better understand the activities by which TP53 mutations, identified in Li-Fraumeni syndrome, contribute to tumorigenesis in vivo, we generated a novel germline p53R245W allele (contact mutation) and compared it to existing p53R172H (structural mutation) and p53R270H (contact mutation) alleles. Thymocytes from heterozygous mice showed all three hot-spot mutations exhibited similar inhibitory effects on wild type p53 transcription in vivo and tumors from these mice had similar levels of loss of heterozygosity. However, the overall survival of p53R245W/+ and p53R270H/+ mice, but not p53R172H/+ mice, was significantly shorter than that of p53+/- mice, demonstrating p53 mutation-specific GOF contributions to tumor development. Furthermore, p53R245W/+ and p53R270H/+ mice had more osteosarcoma metastases than p53R172H/+ mice, indicating that these two contact mutants have stronger GOF in driving osteosarcoma metastasis. Omics analyses using RNA-sequencing data from p53R172H/+, p53R245W/+, and p53R270H/+ primary osteosarcomas in comparison to p53+/- indicated GOF was mediated by distinct pathways among the three mutations. Thus, both the inhibitory effect of mutant over WT p53, and GOF activities of mutant p53 contributed to tumorigenesis in vivo. Targeting p53 mutant-specific pathways may be important for therapeutic outcomes in osteosarcomas. Citation Format: Shunbin Xiong, Dhruv Chachad, Yun Zhang, Jovanka Gencel-Augusto, Mario Sirito, Vinod Pant, Peirong Yang, Chang Sun, Guillermina Lozano. Differences in gain-of-function and inhibitory effects amongst p53 mutants in vivo [abstract]. In: Proceedings of the AACR Special Conference: Cancer Metastasis; 2022 Nov 14-17; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_2):Abstract nr A042.

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues Functional P53β/γ Isoforms in MDM2-amplified Cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Silencing of Mutant P53 by Sirna Induces Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells

RNA Interference Targeting Mutant P53 Inhibits Growth and Induces Apoptosis in DU145 Human Prostate Cancer Cells

Modeling the Etiology of p53-mutated Cancer Cells

Differential Gain-of-Function Activity of Three P53 Hotspot Mutants in Vivo

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Translating p53-based therapies for cancer into the clinic

The Development of P53-Targeted Therapies for Human Cancers

Differences in gainof-function and inhibitory effects amongst p53 mutants in vivo

Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis

Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile

Network effect of Wt-mutant p53 interactions and implications on p53 gene therapy.

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells

Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53 -deficient cancers to mTOR inhibition.

p53-R273H Sustains ROS, Pro-Inflammatory Cytokine Release and mTOR Activation While Reducing Autophagy, Mitophagy and UCP2 Expression, Effects Prevented by wtp53

Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery